Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects

Details for Australian Patent Application No. 2004244756 (hide)

Owner Centelion

Inventors Caron, Anne; Branellec, Didier; Michelet, Sandrine; Schwartz, Bertrand; Caron, Alexis; Rouy, Didier; Emmanuel, Florence; Finiels, Francoise

Agent MIDDLETONS LAWYERS

Pub. Number AU-A-2004244756

PCT Pub. Number WO2004/108167

Priority 60/566,193 28.04.04 US; 60/475,959 05.06.03 US; 60/560,915 09.04.04 US

Filing date 4 June 2004

Wipo publication date 16 December 2004

International Classifications

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

12 January 2006 PCT application entered the National Phase

  PCT publication WO2004/108167 Priority application(s): WO2004/108167

3 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004244763-Elicitor made from trigonella foenum graecum extracts for the treatment of plant pathogens, use thereof, and method for the production thereof

2004244755-Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds